Malaria with other antimalarials (known as artemisinin-combination therapy, or ACT), which decreases resistance to any single drug component. These additional antimalarials include: amodiaquine, lumefantrine, mefloquine or sulfadoxine/pyrimethamine. Another recommended combination is dihydroartemisinin and piperaquine. ACT is about 90% effective when used to treat uncomplicated malaria. To treat malaria during pregnancy, the WHO recommends the use of quinine plus clindamycin early in the pregnancy (1st trimester), and ACT in later stages (2nd and 3rd trimesters). In the 2000s (decade), malaria with partial resistance to artemisins emerged in Southeast Asia. Infection with "P. vivax", "P. ovale" or "P. malariae" usually do not require
Malaria Consortium impact of malaria, illustrating the effects of the disease on families, health workers, malaria researchers and local communities. The exhibition was originally launched for World Malaria Day 2010 at United Nations Headquarters in New York. Malaria Consortium Malaria Consortium is an international non-profit organisation specialising in the comprehensive control of malaria and other communicable diseases – particularly those affecting children under five. Its headquarters are in the United Kingdom, with regional offices in Africa and Asia, and country offices in Cambodia, Ethiopia, Mozambique, Myanmar, Nigeria, South Sudan, Thailand, and Uganda. Malaria Consortium has until recently also worked in Ghana, Senegal,